Xconomy: Amylin Nears Endgame With Icahn, Sciele Pharma Declares Victory in Buyout, Nanogen Files Bankruptcy, & More San Diego Life Sciences News
Summary
Amylin Nears Endgame With Icahn, Sciele Pharma Declares Victory in Buyout, Nanogen Files Bankruptcy, & More San Diego Life Sciences News (Page 2 of 2) conference hosted last week by San Diego’s Wireless Life Sciences Alliance, also said it’s critical to get insurance companies to approve reimbursements for innovative medical technologies.Biogen responded by saying a Big Pharma buyout of the company would create administrative redundancies, add costs, and eliminate dual-use opportunities for certain drugs under development.But the market’s ho-hum valuation of Acadia has CEO Uli Hacksell hoping for a more enthusiastic response when the results of a late-stage trial for the drug become available in four months or so.—Joel Martin, a partner who left San Diego’s Forward Ventures in October, was named as the new president and CEO of Altair Therapeutics.Founded in 2007, privately held Altair is developing therapeutics for respiratory diseases like asthma and rhinitis (a.k.a stuffy, runny nose).